Jove
Visualize
Contact Us

Related Experiment Videos

In vivo models of angiogenesis.

K Norrby1

  • 1Department of Pathology, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden. klas.norrby@pathology.gu.se

Journal of Cellular and Molecular Medicine
|September 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mast cells and de novo angiogenesis: Angiogenic capability of individual mast-cell mediators such as histamine, TNF, IL-8 and bFGF.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2016
Same author

Intratumoral microvascular density in malignant lymphomas of B-cell origin.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2001
Same author

Constitutively synthesized nitric oxide is a physiological negative regulator of mammalian angiogenesis mediated by basic fibroblast growth factor.

International journal of experimental pathology·2001
Same author

Oral administration of a nitric oxide synthase inhibitor enhances de novo mammalian angiogenesis mediated by TNF-alpha, saline and mast-cell secretion.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2001
Same author

Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat.

International journal of cancer·2001
Same author

2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis.

International journal of experimental pathology·2000
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

This review evaluates preclinical animal models for studying angiogenesis, crucial for developing new therapies for cancer, eye diseases, and tissue repair. It discusses various assays, highlighting their pros and cons for drug development.

Area of Science:

  • Vascular Biology and Medicine
  • Preclinical Research Models
  • Drug Discovery and Development

Background:

  • Angiogenesis (new blood vessel formation) and anti-angiogenesis are vital for human health, impacting wound healing, tissue growth, and diseases like cancer and macular degeneration.
  • Therapeutic strategies targeting angiogenesis offer significant potential benefits for millions worldwide, with anti-angiogenic treatments already established in clinical practice.
  • Pro-angiogenic therapies are also under development for conditions such as myocardial or cerebral hypoxia and poor wound healing.

Purpose of the Study:

  • To review and critically assess current and emerging preclinical assays used to study angiogenesis and anti-angiogenesis.
  • To compare these assays based on biological, technical, economic, and ethical considerations.
  • To provide detailed insights into specific assays, including the rodent mesenteric-window assay.

Related Experiment Videos

Main Methods:

  • Comprehensive review of major preclinical angiogenesis assays.
  • Discussion of assays including corneal micropocket, chick chorioallantoic membrane, rodent mesentery, subcutaneous sponge/matrix/alginate microbead, Matrigel plug, disc, directed in vivo assays, and the zebrafish system.
  • Inclusion of quantitative techniques for assessing angiogenesis in patients.

Main Results:

  • Currently utilized preclinical assays vary significantly in efficacy and relevance to human disease.
  • Different assays are suited for distinct research purposes, such as high-throughput screening, dosage-effect studies, or evaluating drug combinations.
  • The rodent mesenteric-window assay, a valuable tool, has not been extensively covered in previous reviews.

Conclusions:

  • No single preclinical angiogenesis assay is universally superior; assay selection depends on the specific research question and therapeutic goal.
  • A thorough understanding of assay limitations and strengths is essential for effective drug development in angiogenesis-related diseases.
  • Further research and refinement of existing and novel assays are needed to improve the translation of preclinical findings to clinical applications.